X4 Pharmaceuticals (NASDAQ: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the fourth quarter and year ended December 31, 2025 ,and provided a corporate update.
“Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver life-changing therapies to people living with rare blood diseases,” said Executive Chairman Adam Craig.
• Net product sales of $2.3 million and $6.5 million for the three and twelve months ended December 31, 2025, respectively, were entirely attributable to XOLREMDI product sales in the United States.
• License and other revenue of $0.3 million and $28.6 million for the three and twelve months ended December 31, 2025, respectively, were entirely attributable to the Company's Norgine out-licensing agreement.
• Operating loss was $23.7 million and $86.9 million for the three and twelve months ended December 31, 2025, respectively.
• Net loss for the three and twelve months ended December 31, 2025 was $23.9 million, or $(0.22) per share, and $79.2 million, or $(1.87) per share, respectively.
• Cash, cash equivalents and short-term investments totaled $253.0 million as of December 31, 2025, which management believes will enable the Company to fund its operations through 2028.
XFOR shares acquired 25 cents, or 7%, to $3.81.
